VaxInnate Quadrivalent Seasonal Influenza Vaccine

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints

Cranbury, NJ, Nov. 11, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering next-generation vaccine technology, announced today that enrollment has concluded in the Phase 1 study of the Company's experimental recombinant quadrivalent seasonal influenza vaccine, VAX2012Q . Top-line results showed that doses as low as 2 mcg per component were immunogenic, with mean seroprotection rates exceeding 90% for each of the four vaccine components at the day 21 clinic visit. VAX2012Q was generally well tolerated, with mild to moderate arm pain the most commonly reported adverse event. Complete study results will be submitted for future publication.

"VAX2012Q continues to show great promise as a seasonal influenza vaccine in adults," commented Dr. Lynda Tussey , vice president of research and development at VaxInnate. "Based on these top-line results, and pending the completion of our planned Phase 1b/2 study in elderly individuals that will begin later this month, we expect to advance VAX2012Q into a Phase 2 study in healthy adults 18 years of age and older in 2015. This next stage of clinical development will confirm the VAX2012Q dose in adult and elderly individuals, and will support further development and pursuit of licensure."

This Phase 1 trial enrolled 316 healthy adults aged 18-40 who were each evaluated for vaccine tolerability and immune response at 21 days post-vaccination. Study participants will be monitored for one year following their vaccination to assess long-term safety. The trial was funded under Contract No. HHSO100201100011C from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.

Wayne Pisano , VaxInnate's president and chief executive officer, commented, "These immunogenicity results, combined with our advanced recombinant technology, will ensure reliability of supply and the ability to manufacture vaccine rapidly - potentially reducing total production times from the typical six-to-nine month turnaround to just three months." 

"We believe this represents a significant value considering that the demand in the U.S. alone has increased to nearly 150 million doses annually. With this growing demand and given that most influenza immunizations occur in an 8-week period, current manufacturing technologies and capacities have historically struggled to keep up," Pisano continued. "And with the recent recommendation to add a 4 th influenza strain to the seasonal vaccine, there is even greater pressure on the current technologies and manufacturing capacities.  We believe that VAX2012Q and our recombinant manufacturing technology have strong commercial potential in this market, and look forward to reporting additional data from our upcoming studies in 2015."

Powerful Vaccine Technology Platform             

VaxInnate's technology platform is based on proprietary Toll-like Receptor (TLR) technology, which potentiates the immune response. The TLR technology genetically fuses vaccine antigens to the bacterial protein flagellin, and this sequentially triggers the innate and adaptive immune systems. Using this technology, vaccines can be produced using low-cost, highly scalable recombinant DNA techniques, thus avoiding many of the challenges of conventional vaccine production. This technology has the potential for production of significantly greater quantities of vaccine in extremely rapid timeframes, with very low infrastructure costs.

About VaxInnate

VaxInnate is a privately held biotechnology company in Cranbury, NJ that is pioneering a breakthrough technology platform for use in developing novel and proprietary vaccines. Influenza vaccines manufactured using this technology have demonstrated excellent immunogenicity in the elderly population, a group that is typically less responsive to influenza vaccines. VaxInnate's vaccines focus on infectious diseases, including seasonal and pandemic influenza, Clostridium difficile and dengue. VaxInnate's ongoing studies of seasonal and pandemic flu vaccines are significantly funded under Contract No. HHSO100201100011C with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS).

To learn more about VaxInnate and to explore the company's technology platform, please visit the website at www.vaxinnate.com .

Christine C. Mayer VaxInnate Corporation Aline B. Schimmel Scienta Communications

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 34

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 31

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 67

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 47

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 46

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 0

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 32

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 311

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 131

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 106

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading

Top 5 Most Recently Viewed Articles

Big Lots Adjusts Strategy Amid Bankruptcy Process Challenges

Updated Category News Views 183

Big Lots Updates on Court-Supervised Process No Longer Anticipates Closing Previously Announced Sale to Nexus Capital Management Continues Efforts Towards a Going Concern Transaction Gearing Up for Going Out of Business Sales at Remaining Locations Big Lots, Inc. has recently made crucial updates regarding its financial restructuring efforts. The company has announced...

Continue Reading
Detailed Overview of Man Group PLC's Stake in American Axle

Updated Category News Views 133

Key Information About Man Group PLC's Disclosures FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE This document represents a disclosure by a person with interests in relevant securities, specifically when owning 1% or more of American Axle & Manufacturing Holdings, Inc. As per Rule 8.3 of the Takeover Code, certain details regarding the interests and...

Continue Reading
Westlake Chemical Gets Boost from Analysts with New Targets

Updated Category News Views 67

Westlake Chemical Upgraded to Neutral Recently, BofA Securities made a notable adjustment regarding Westlake Chemical (NASDAQ: WLK), changing the stock's rating from Underperform to Neutral. This upgrade included raising the price target to $159 from $151, reflecting a more balanced view on the company's trajectory. The changes stem from a reassessment that weighs current...

Continue Reading
Envision Energy Recognized Among Leading Climate Tech Innovators

Updated Category News Views 209

Envision Energy's Recognition in Climate Technology Envision Energy has earned a well-deserved place on a prestigious list recognizing transformative companies in climate technology. This acknowledgment highlights their significant contributions in the fight against climate change through innovative renewable energy solutions. A Global Leader in Renewable Energy Known for...

Continue Reading
Exploring Franco-Nevada's Ten-Year Investment Journey

Updated Category News Views 155

Understanding Franco-Nevada's Investment Growth Franco-Nevada (NYSE: FNV) has showcased impressive performance over the last decade, delivering an average annual return of 14.64%. With a market capitalization of $30.52 billion, it has consistently outperformed the overall market by 3.21% on an annualized basis. The Impact of Compounding Returns Let's say an investor...

Continue Reading